Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 3.81
PMD's Cash-to-Debt is ranked lower than
56% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. PMD: 3.81 )
Ranked among companies with meaningful Cash-to-Debt only.
PMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.27  Med: No Debt Max: No Debt
Current: 3.81
Equity-to-Asset 0.68
PMD's Equity-to-Asset is ranked higher than
64% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PMD: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
PMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.82 Max: 0.96
Current: 0.68
0.4
0.96
Debt-to-Equity 0.09
PMD's Debt-to-Equity is ranked higher than
75% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. PMD: 0.09 )
Ranked among companies with meaningful Debt-to-Equity only.
PMD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.14 Max: 0.83
Current: 0.09
0.01
0.83
Debt-to-EBITDA 0.12
PMD's Debt-to-EBITDA is ranked higher than
92% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. PMD: 0.12 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PMD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.12  Med: 1.09 Max: 1.84
Current: 0.12
0.12
1.84
Interest Coverage 144.81
PMD's Interest Coverage is ranked higher than
56% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. PMD: 144.81 )
Ranked among companies with meaningful Interest Coverage only.
PMD' s Interest Coverage Range Over the Past 10 Years
Min: 144.81  Med: No Debt Max: No Debt
Current: 144.81
Piotroski F-Score: 8
Altman Z-Score: 10.12
Beneish M-Score: -3.21
WACC vs ROIC
7.53%
43.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 24.19
PMD's Operating Margin % is ranked higher than
95% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PMD: 24.19 )
Ranked among companies with meaningful Operating Margin % only.
PMD' s Operating Margin % Range Over the Past 10 Years
Min: 5.45  Med: 20.88 Max: 29.06
Current: 24.19
5.45
29.06
Net Margin % 15.06
PMD's Net Margin % is ranked higher than
92% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. PMD: 15.06 )
Ranked among companies with meaningful Net Margin % only.
PMD' s Net Margin % Range Over the Past 10 Years
Min: 5.6  Med: 12.97 Max: 18.25
Current: 15.06
5.6
18.25
ROE % 38.50
PMD's ROE % is ranked higher than
100% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. PMD: 38.50 )
Ranked among companies with meaningful ROE % only.
PMD' s ROE % Range Over the Past 10 Years
Min: 12.33  Med: 27.12 Max: 48.96
Current: 38.5
12.33
48.96
ROA % 24.38
PMD's ROA % is ranked higher than
98% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. PMD: 24.38 )
Ranked among companies with meaningful ROA % only.
PMD' s ROA % Range Over the Past 10 Years
Min: 6.55  Med: 22.36 Max: 31.12
Current: 24.38
6.55
31.12
ROC (Joel Greenblatt) % 60.98
PMD's ROC (Joel Greenblatt) % is ranked higher than
91% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. PMD: 60.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.62  Med: 72.02 Max: 202.99
Current: 60.98
8.62
202.99
3-Year Revenue Growth Rate 12.10
PMD's 3-Year Revenue Growth Rate is ranked higher than
68% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. PMD: 12.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10  Med: 10.15 Max: 134.5
Current: 12.1
-10
134.5
3-Year EBITDA Growth Rate 22.30
PMD's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. PMD: 22.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -31.3  Med: 7.1 Max: 47.1
Current: 22.3
-31.3
47.1
3-Year EPS without NRI Growth Rate 19.20
PMD's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. PMD: 19.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -55  Med: 0 Max: 138.1
Current: 19.2
-55
138.1
GuruFocus has detected 3 Warning Signs with Psychemedics Corp PMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PMD's 30-Y Financials

Financials (Next Earnings Date: 2018-02-06)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

PMD Guru Trades in Q4 2016

Jim Simons 499,990 sh (+15.02%)
Chuck Royce 37,500 sh (unchged)
» More
Q1 2017

PMD Guru Trades in Q1 2017

Chuck Royce 37,500 sh (unchged)
Jim Simons 467,400 sh (-6.52%)
» More
Q2 2017

PMD Guru Trades in Q2 2017

Chuck Royce 37,500 sh (unchged)
Jim Simons 456,500 sh (-2.33%)
» More
Q3 2017

PMD Guru Trades in Q3 2017

Jim Simons 491,000 sh (+7.56%)
Chuck Royce 37,771 sh (+0.72%)
» More
» Details

Insider Trades

Latest Guru Trades with PMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:TSE:9707, NZSE:PEB, XAMS:CURE, XKRX:086040, LSE:ONC, NAS:TRIB, XTER:ECX, XKRX:950140, XKRX:217600, NAS:VRML, SGX:1B1, XPAR:CLNV, OCSE:BIOPOR, NAS:CEMI, ASX:VHT, TSE:4595, OSL:GENT-ME, NAS:CODX, XKRX:246720, ROCO:4155 » details
Headquarter Location:USA
Psychemedics Corp provides testing services for the detection of drugs of abuse through the analysis of hair samples. This information is useful to employers for both applicant and employee testing, as well as to physicians and among others.

Psychemedics Corp provides testing services for the detection of drugs of abuse through the analysis of hair samples. This information is useful to employers for both applicant and employee testing, as well as to physicians and among others.

Top Ranked Articles about Psychemedics Corp

Psychemedics Corporation Announces Q3 Earnings
Psychemedics Announces Addition of FDA-Cleared Benzodiazepines Hair Test
Psychemedics Corporation Launches Synthetic Cannabinoids Hair Test
Psychemedics Corporation - First Lab Approved For Hair Testing In Iowa
Psychemedics Corporation Announces Q2 Earnings
Psychemedics Corporation Announces Record Q1 Revenues And Earnings
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Psychemedics Corporation (PMD) & Lead Plaintiff Deadline - April 3, 2017

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) and certain of its officers, on behalf of a class who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pmd.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate Psychemedics Brasil Exames Toxicológicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) effectively, Psychemedics lacked effective internal controls over financial reporting; and (3) consequently, Psychemedics’ public statements were materially false and misleading at all relevant times.
On January 31, 2017, it was revealed that Psychemedics Brasil Exames Toxicológicos Ltda., Psychemedics’ local representative in Brazil, was ordered to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for “preventing other companies from accessing (the) market,” on January 20, 2017. Following this news, Psychemedics stock dropped during intra-day trading on January 31, 2017. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/pmd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Psychemedics Corporation To Contact The Firm

STEVENSON, Md., March 29, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Psychemedics Corporation (NASDAQ:PMD) (“Psychemedics” or the “Company”) common stock during the period between February 28, 2014 and January 31, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Psychemedics common stock during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of the conduct. According to the complaint, following a January 31, 2017 press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and liable for millions in losses, the value of Psychemedics shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Psychemedics common stock purchased on or after February 28, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
PMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Psychemedics Corporation and a Lead Plaintiff Deadline of April 3, 2017

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Psychemedics Corporation (NASDAQ:PMD) securities between February 28, 2014 and January 30, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/psychemedics-corporation. There is no cost or obligation to you. According to the complaint, throughout the Class Period, Psychemedics issued materially false and/or misleading statements and/or failed to disclose that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of this conduct. On January 31, 2017, Psychemedics issued a press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and is liable for millions in losses. If you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/psychemedics-corporation. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Psychemedics Corporation

Sets Lead Plaintiff Deadline of April 3, 2017 -- PMD

NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Psychemedics Corporation (“Psychemedics”) (NASDAQ:PMD) between February 28, 2014 and January 30, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Daly v. Psychemedics Corporation, et al. (Case No. 1:17-cv-10186) in the USDC for the District of Massachusetts. Click here to view the complaint. To get more information go to: http://www.zlk.com/pslra/psychemedics-corporation or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that, among other allegations, throughout the Class Period Psychemedics issued materially false and/or misleading statements and/or failed to disclose that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of this conduct. On January 31, 2017, Psychemedics issued a press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and is liable for millions in losses. Take Action: if you suffered a loss in Psychemedics you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.26
PMD's PE Ratio is ranked higher than
92% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. PMD: 16.26 )
Ranked among companies with meaningful PE Ratio only.
PMD' s PE Ratio Range Over the Past 10 Years
Min: 9.07  Med: 19.78 Max: 64.78
Current: 16.26
9.07
64.78
PE Ratio without NRI 16.26
PMD's PE Ratio without NRI is ranked higher than
92% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. PMD: 16.26 )
Ranked among companies with meaningful PE Ratio without NRI only.
PMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.07  Med: 19.78 Max: 64.78
Current: 16.26
9.07
64.78
Price-to-Owner-Earnings 14.52
PMD's Price-to-Owner-Earnings is ranked higher than
85% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. PMD: 14.52 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.5  Med: 21.77 Max: 185.89
Current: 14.52
7.5
185.89
PB Ratio 5.75
PMD's PB Ratio is ranked lower than
69% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. PMD: 5.75 )
Ranked among companies with meaningful PB Ratio only.
PMD' s PB Ratio Range Over the Past 10 Years
Min: 1.98  Med: 5.63 Max: 9.8
Current: 5.75
1.98
9.8
PS Ratio 2.45
PMD's PS Ratio is ranked higher than
67% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. PMD: 2.45 )
Ranked among companies with meaningful PS Ratio only.
PMD' s PS Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.55 Max: 4.48
Current: 2.45
0.91
4.48
Price-to-Free-Cash-Flow 11.60
PMD's Price-to-Free-Cash-Flow is ranked higher than
84% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. PMD: 11.60 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.64  Med: 19.01 Max: 86.36
Current: 11.6
6.64
86.36
Price-to-Operating-Cash-Flow 9.69
PMD's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. PMD: 9.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.92  Med: 15.32 Max: 22.42
Current: 9.69
5.92
22.42
EV-to-EBIT 9.66
PMD's EV-to-EBIT is ranked higher than
93% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. PMD: 9.66 )
Ranked among companies with meaningful EV-to-EBIT only.
PMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 11.7 Max: 81.9
Current: 9.66
4.1
81.9
EV-to-EBITDA 7.53
PMD's EV-to-EBITDA is ranked higher than
93% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. PMD: 7.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
PMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.7  Med: 10.7 Max: 28.4
Current: 7.53
3.7
28.4
EV-to-Revenue 2.33
PMD's EV-to-Revenue is ranked higher than
72% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. PMD: 2.33 )
Ranked among companies with meaningful EV-to-Revenue only.
PMD' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 2.4 Max: 4.2
Current: 2.33
0.7
4.2
PEG Ratio 3.88
PMD's PEG Ratio is ranked lower than
57% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.98 vs. PMD: 3.88 )
Ranked among companies with meaningful PEG Ratio only.
PMD' s PEG Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.37 Max: 132.86
Current: 3.88
0.47
132.86
Shiller PE Ratio 26.74
PMD's Shiller PE Ratio is ranked higher than
74% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. PMD: 26.74 )
Ranked among companies with meaningful Shiller PE Ratio only.
PMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 6.64  Med: 18.79 Max: 39.85
Current: 26.74
6.64
39.85
Current Ratio 2.72
PMD's Current Ratio is ranked higher than
57% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. PMD: 2.72 )
Ranked among companies with meaningful Current Ratio only.
PMD' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 4.8 Max: 18.17
Current: 2.72
0.67
18.17
Quick Ratio 2.72
PMD's Quick Ratio is ranked higher than
64% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PMD: 2.72 )
Ranked among companies with meaningful Quick Ratio only.
PMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.72 Max: 17.83
Current: 2.72
0.56
17.83
Days Sales Outstanding 48.61
PMD's Days Sales Outstanding is ranked higher than
75% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. PMD: 48.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
PMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.89  Med: 57.01 Max: 70.9
Current: 48.61
47.89
70.9
Days Payable 20.90
PMD's Days Payable is ranked lower than
94% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. PMD: 20.90 )
Ranked among companies with meaningful Days Payable only.
PMD' s Days Payable Range Over the Past 10 Years
Min: 8.99  Med: 22.11 Max: 36.51
Current: 20.9
8.99
36.51

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.34
PMD's Dividend Yield % is ranked higher than
86% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.89 vs. PMD: 3.34 )
Ranked among companies with meaningful Dividend Yield % only.
PMD' s Dividend Yield % Range Over the Past 10 Years
Min: 2.25  Med: 4.58 Max: 18.28
Current: 3.34
2.25
18.28
Dividend Payout Ratio 0.54
PMD's Dividend Payout Ratio is ranked lower than
68% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PMD: 0.54 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PMD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.98 Max: 2.14
Current: 0.54
0.49
2.14
Forward Dividend Yield % 3.40
PMD's Forward Dividend Yield % is ranked higher than
83% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. PMD: 3.40 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.91
PMD's 5-Year Yield-on-Cost % is ranked higher than
81% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. PMD: 3.91 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PMD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.63  Med: 5.36 Max: 21.4
Current: 3.91
2.63
21.4
3-Year Average Share Buyback Ratio -0.90
PMD's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. PMD: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.8  Med: -0.5 Max: 1.9
Current: -0.9
-32.8
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 23.75
PMD's Price-to-Net-Current-Asset-Value is ranked lower than
91% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.01 vs. PMD: 23.75 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.37  Med: 10.67 Max: 660.67
Current: 23.75
3.37
660.67
Price-to-Tangible-Book 5.75
PMD's Price-to-Tangible-Book is ranked lower than
53% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. PMD: 5.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.97  Med: 7.6 Max: 25.49
Current: 5.75
2.97
25.49
Price-to-Intrinsic-Value-Projected-FCF 1.70
PMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
52% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. PMD: 1.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.68  Med: 2.48 Max: 13.87
Current: 1.7
0.68
13.87
Price-to-Median-PS-Value 0.96
PMD's Price-to-Median-PS-Value is ranked higher than
56% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PMD: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.65 Max: 37.88
Current: 0.96
0.55
37.88
Price-to-Peter-Lynch-Fair-Value 1.28
PMD's Price-to-Peter-Lynch-Fair-Value is ranked higher than
76% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. PMD: 1.28 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.72 Max: 14.78
Current: 1.28
0.7
14.78
Price-to-Graham-Number 2.04
PMD's Price-to-Graham-Number is ranked higher than
72% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.40 vs. PMD: 2.04 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 3.08 Max: 10.79
Current: 2.04
1.27
10.79
Earnings Yield (Greenblatt) % 10.36
PMD's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. PMD: 10.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 8.6 Max: 24.3
Current: 10.36
1.2
24.3
Forward Rate of Return (Yacktman) % 15.99
PMD's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. PMD: 15.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.6  Med: 6.8 Max: 40.8
Current: 15.99
-9.6
40.8

More Statistics

Revenue (TTM) (Mil) $40.71
EPS (TTM) $ 1.11
Beta0.92
Short Percentage of Float0.65%
52-Week Range $13.81 - 27.99
Shares Outstanding (Mil)5.49

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}